Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr;20(4):322-334.
doi: 10.6004/jnccn.2022.0021.

NCCN Guidelines® Insights: Hodgkin Lymphoma, Version 2.2022

Richard T Hoppe  1 , Ranjana H Advani  1 , Weiyun Z Ai  2 , Richard F Ambinder  3 , Philippe Armand  4 , Celeste M Bello  5 , Cecil M Benitez  6 , Weina Chen  7 , Bouthaina Dabaja  8 , Megan E Daly  9 , Leo I Gordon  10 , Neil Hansen  11 , Alex F Herrera  12 , Ephraim P Hochberg  13 , Patrick B Johnston  14 , Mark S Kaminski  15 , Christopher R Kelsey  16 , Vaishalee P Kenkre  17 , Nadia Khan  18 , Ryan C Lynch  19 , Kami Maddocks  20 , Jonathan McConathy  21 , Monika Metzger  22 , David Morgan  23 , Carolyn Mulroney  24 , Sheeja T Pullarkat  6 , Rachel Rabinovitch  25 , Karen C Rosenspire  26 , Stuart Seropian  27 , Randa Tao  28 , Pallawi Torka  29 , Jane N Winter  10 , Joachim Yahalom  30 , Joanna C Yang  31 , Jennifer L Burns  32 , Mallory Campbell  32 , Hema Sundar  32
Affiliations

NCCN Guidelines® Insights: Hodgkin Lymphoma, Version 2.2022

Richard T Hoppe et al. J Natl Compr Canc Netw. 2022 Apr.

Abstract

Hodgkin lymphoma (HL) is an uncommon malignancy of B-cell origin. Classical HL (cHL) and nodular lymphocyte-predominant HL are the 2 main types of HL. The cure rates for HL have increased so markedly with the advent of modern treatment options that overriding treatment considerations often relate to long-term toxicity. These NCCN Guidelines Insights discuss the recent updates to the NCCN Guidelines for HL focusing on (1) radiation therapy dose constraints in the management of patients with HL, and (2) the management of advanced-stage and relapsed or refractory cHL.

PubMed Disclaimer

LinkOut - more resources